Glanzmann's thrombasthenia risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors that increase [[autoantibodies]] production in [[acquired]] Glanzmann thrombasthenia include: | Common risk factors that increase [[autoantibodies]] production in [[acquired]] [[Glanzmann's thrombasthenia|Glanzmann thrombasthenia]] include: | ||
* [[Hematologic disorders]] and [[malignancies]], such as : | * [[Hematologic disorders]] and [[malignancies]], such as : | ||
# [[acute lymphoblastic leukemia]] | # [[acute lymphoblastic leukemia]] | ||
Line 17: | Line 17: | ||
# [[myelodysplastic syndrome]] | # [[myelodysplastic syndrome]] | ||
# [[immune thrombocytopenic purpura]] ([[ITP]]) | # [[immune thrombocytopenic purpura]] ([[ITP]]) | ||
* Autoimmune diseases, such as [[Systemic lupus erythematosus| | * Autoimmune diseases, such as [[Systemic lupus erythematosus|Lupus]] <ref name="pmid24979837">{{cite journal| author=Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A| title=Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies. | journal=Isr Med Assoc J | year= 2014 | volume= 16 | issue= 5 | pages= 307-10 | pmid=24979837 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24979837 }}</ref> | ||
* Drugs : [[anti-thrombotic]] drugs use , like [[abciximab]], [[eptifibatide]], and [[tirofiban]] which all antagonize [[αIIbβ3]] | * Drugs : [[anti-thrombotic]] drugs use , like [[abciximab]], [[eptifibatide]], and [[tirofiban]] which all antagonize [[αIIbβ3]] | ||
* | * Platelet [[transfusions]]. <ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | ||
==References== | ==References== |
Revision as of 21:09, 15 November 2018
Glanzmann's thrombasthenia |
Differentiating Glanzmann's thrombasthenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glanzmann's thrombasthenia risk factors On the Web |
American Roentgen Ray Society Images of Glanzmann's thrombasthenia risk factors |
Risk calculators and risk factors for Glanzmann's thrombasthenia risk factors |
- Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The most potent risk factor in the heritable Glanzmann thrombasthenia is consanguineous marriage. [1]
Autoantibodies production cause of acquired Glanzmann thrombasthenia .
Risk Factors
Common risk factors that increase autoantibodies production in acquired Glanzmann thrombasthenia include:
- Hematologic disorders and malignancies, such as :
- acute lymphoblastic leukemia
- non-Hodgkin’s lymphoma
- multiple myeloma
- hairy cell leukemia
- myelodysplastic syndrome
- immune thrombocytopenic purpura (ITP)
- Autoimmune diseases, such as Lupus [2]
- Drugs : anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3
- Platelet transfusions. [3]
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMC 5922622. PMID 10.1002/ajh.20159 DOI: 10.1002/ajh.20159 Check
|pmid=
value (help). - ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). "Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies". Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.